par Mano, Max S.;Awada, Ahmad
;Minisini, A;Durbecq, Virginie
;Di Leo, Angelo
;Piccart-Gebhart, Martine 
Référence Breast, 13, 4, page (347-349)
Publication Publié, 2004-08




Référence Breast, 13, 4, page (347-349)
Publication Publié, 2004-08
Article révisé par les pairs
Résumé : | We report on the case of a patient with a diagnosis of a HER2-overexpressing metastatic breast cancer which was refractory to a combination of a Raf kinase inhibitor and docetaxel, but highly sensitive to trastuzumab, a HER2-targeted monoclonal antibody. Interestingly, there was no evidence of Ras-Raf-MAPK or PI3K-Akt pathways activation. |